SeekingAlpha · Nov 18, 2026
Crescent Capital: Medium-Quality BDC With 2 Catalysts For Growth
Crescent Capital (CCAP) stock remains a strong buy as its 43% NAV discount is exaggerated; a 0.8x fair-value P/NAV supports a $14.18 target.
NYSE · CCAP
Financial Services · Asset Management
$9.92
Up+$0.04 (+0.40%)
Updated Nov 19, 2026, 1:27 PM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CCAP
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 18, 2026
CCAP closed at $9.92 after 21 trading sessions, up 16.71% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 18, 2026 | $9.80 | $10.005 | $9.80 | $9.92 | 253.18K |
| Nov 17, 2026 | $10.00 | $10.03 | $9.85 | $9.88 | 182.11K |
| Nov 16, 2026 | $10.21 | $10.21 | $10.035 | $10.08 | 181.28K |
| Nov 13, 2026 | $10.18 | $10.245 | $9.95 | $10.13 | 214.59K |
| Nov 12, 2026 | $10.22 | $10.22 | $10.0118 | $10.10 | 160.07K |
| Nov 11, 2026 | $10.25 | $10.38 | $10.075 | $10.25 | 396.18K |
| Nov 10, 2026 | $9.90 | $10.408 | $9.70 | $10.38 | 536.8K |
| Nov 9, 2026 | $9.42 | $9.5639 | $9.21 | $9.24 | 215.37K |
| Nov 6, 2026 | $9.34 | $9.4999 | $9.3001 | $9.38 | 146.92K |
| Nov 5, 2026 | $9.66 | $9.75 | $9.26 | $9.45 | 191.65K |
| Nov 4, 2026 | $9.50 | $9.72 | $9.485 | $9.64 | 174.07K |
| Nov 3, 2026 | $9.44 | $9.44 | $9.24 | $9.35 | 167.52K |
| Nov 2, 2026 | $9.29 | $9.44 | $9.28 | $9.415 | 103.01K |
| Oct 30, 2026 | $9.30 | $9.32 | $9.1001 | $9.27 | 233.46K |
| Oct 29, 2026 | $9.03 | $9.30 | $9.00 | $9.30 | 172.22K |
| Oct 28, 2026 | $8.85 | $9.02 | $8.85 | $9.01 | 130.2K |
| Oct 27, 2026 | $8.75 | $8.9237 | $8.75 | $8.90 | 189.35K |
| Oct 26, 2026 | $8.63 | $8.73 | $8.555 | $8.70 | 144.89K |
| Oct 23, 2026 | $8.68 | $8.795 | $8.56 | $8.66 | 105.63K |
| Oct 22, 2026 | $8.50 | $8.815 | $8.47 | $8.76 | 184.07K |
| Oct 21, 2026 | $8.53 | $8.65 | $8.395 | $8.50 | 175.67K |
The latest Smart Investors Daily articles mentioning CCAP.
Company
Market Activity
Research & News
CCAP research
Company profile and research snapshot.
Crescent Capital BDC Inc is a business development company structured as an externally managed, closed-end, non-diversified management investment company. The company's primary investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through debt and related equity investments. It will seek to achieve its investment objectives by investing in secured debt (including senior secured, unitranche, and second lien debt) and unsecured debt (including senior unsecured, mezzanine, and subordinated debt), as well as related equity securities of private U.S. middle-market companies.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 11, 2026 | Wells Fargo | Equal-Weight | — |
| Nov 11, 2026 | Ladenburg Thalmann | Neutral | — |
| Sep 10, 2026 | B of A Securities | Neutral | — |
| Aug 17, 2026 | Keefe, Bruyette & Woods | Market Perform | — |
| Aug 12, 2026 | B. Riley Securities | Neutral | — |
No generated briefing is available yet.
SeekingAlpha · Nov 18, 2026
Crescent Capital (CCAP) stock remains a strong buy as its 43% NAV discount is exaggerated; a 0.8x fair-value P/NAV supports a $14.18 target.
Benzinga · Nov 11, 2026
Wells Fargo analyst Finian O'Shea maintains Crescent Capital BDC (NASDAQ:CCAP) with a Equal-Weight and lowers the price target from $11 to $10.
Yahoo · Nov 11, 2026
Crescent Capital BDC Inc (CCAP) posted $0.37 per share in net investment income, announced a $50 million buyback and a new joint venture to accelerate leverage reduction amid a subdued LBO market.
Yahoo · Nov 10, 2026
Add-on financings now make up half of Crescent's deal count, a shift that shapes how the firm is working through a slow buyout market.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning CCAP.